Dr. Sebastian G. De La Fuente, MD

Dr. De La Fuente practices at Adventhealth Diabetes Institute Orlando - HOPD in Orlando, Florida.

Dr. De La Fuente's NPI, 1669647921, was assigned on April 28, 2008. Dr. De La Fuente graduated from Univ Salvador- Fac Med in 1998. Dr. De La Fuente holds Florida license ME106946.

Dr. De La Fuente's primary practice is Adventhealth Diabetes Institute Orlando - HOPD, at 2415 N Orange Ave, Orlando, FL 32804.

Dr. De La Fuente's primary practice is Adventhealth Diabetes Institute Orlando - HOPD in Orlando, Florida. Dr. De La Fuente is also affiliated with AdventHealth Orlando. The medical group on file is AdventHealth Medical Group. Dmand AI also links Dr. De La Fuente to 1 more hospital and 1 group practice or clinic, each named with a free account. Dr. De La Fuente's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. De La Fuente practices, 4 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. De La Fuente's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. De La Fuente is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. De La Fuente's licenses on file in 3 states: Florida, Massachusetts and North Carolina.

Dmand AI lists cancerous skin growth removal, esophagus, stomach, or upper small intestine surgery, gallbladder removal, groin hernia surgery and removal of damaged skin or skin graft among the conditions Dr. De La Fuente treats.

CMS data shows 250 Medicare services from Dr. De La Fuente across 9 procedure codes in 2024, for 170 Medicare patients. Medicare paid $20,208 for them.

CMS counts 170 Medicare patients who saw Dr. De La Fuente in 2024. The largest group is 65 to 74, with 75 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.95, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. De La Fuente's median patient age at 68, with 53% women.

In 2024, Dr. De La Fuente wrote 45 Medicare Part D claims for 16 patients. 53% of them were for generic drugs. CMS names the drug for 19 of them, across 1 drug with 11 or more claims each, at $24,150 in total drug cost. In 2023, CMS named 72 claims across 4 drugs.

Dr. De La Fuente accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. De La Fuente as offering telehealth.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 43 papers to Dr. De La Fuente, published from 2003 to 2023. 2012 was the busiest year, with 4. The most frequent topics are Pancreatic Neoplasms, Postoperative Complications and Laparoscopy. Dr. De La Fuente has published most often in J Gastrointest Surg. Dr. De La Fuente's most frequent co-authors are Kirk A. Ludwig, MD, Bryan M. Clary, MD and Juan Pablo Arnoletti, MD.

CMS Open Payments shows 115 general payments to Dr. De La Fuente from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 62% of the total. Transenterix, Inc. paid the most, $14,933.

Dmand AI lists 2 awards for Dr. De La Fuente, most recently Outstanding Clinical Research Award in Gastrointestinal Cancers in 2012.

Dr. De La Fuente graduated from Univ Salvador- Fac Med in 1998. Dr. De La Fuente is a member of ACS, ASCO, AAS, SSAT and SAGES.

Dr. De La Fuente is in network with 20 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.